EA202090243A1 - Способы инактивации вирусных загрязнений - Google Patents

Способы инактивации вирусных загрязнений

Info

Publication number
EA202090243A1
EA202090243A1 EA202090243A EA202090243A EA202090243A1 EA 202090243 A1 EA202090243 A1 EA 202090243A1 EA 202090243 A EA202090243 A EA 202090243A EA 202090243 A EA202090243 A EA 202090243A EA 202090243 A1 EA202090243 A1 EA 202090243A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
inactivating viral
viral contaminations
contaminations
antibody
Prior art date
Application number
EA202090243A
Other languages
English (en)
Inventor
Филипа Абрантес
Соня Летесту
Лаура Каюзак
Лионель Дуарте
Original Assignee
Икнос Сайенсиз Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Икнос Сайенсиз Са filed Critical Икнос Сайенсиз Са
Publication of EA202090243A1 publication Critical patent/EA202090243A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Water Supply & Treatment (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Настоящее изобретение относится к способу получения содержащего антитело раствора, который свободен от загрязнения вирусами, с культивируемыми клетками в качестве исходного материала. Данный способ включает стадию воздействия на раствор, содержащий антитело, смесью растворителя и детергента или высоким pH.
EA202090243A 2017-08-25 2018-08-27 Способы инактивации вирусных загрязнений EA202090243A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17188012.3A EP3446710A1 (en) 2017-08-25 2017-08-25 Methods of inactivating viral contaminants
PCT/IB2018/056502 WO2019038742A1 (en) 2017-08-25 2018-08-27 METHODS OF INACTIVATION OF VIRAL CONTAMINANTS

Publications (1)

Publication Number Publication Date
EA202090243A1 true EA202090243A1 (ru) 2020-10-19

Family

ID=59738200

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090243A EA202090243A1 (ru) 2017-08-25 2018-08-27 Способы инактивации вирусных загрязнений

Country Status (13)

Country Link
US (4) US20200369747A1 (ru)
EP (2) EP3446710A1 (ru)
JP (2) JP2021506226A (ru)
KR (1) KR20200045485A (ru)
CN (2) CN115716871A (ru)
AU (2) AU2018320524B2 (ru)
BR (1) BR112020003560A2 (ru)
CA (1) CA3073309A1 (ru)
EA (1) EA202090243A1 (ru)
IL (1) IL272779A (ru)
MX (1) MX2020001920A (ru)
NZ (1) NZ761396A (ru)
WO (1) WO2019038742A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3446710A1 (en) 2017-08-25 2019-02-27 Glenmark Pharmaceuticals S.A. Methods of inactivating viral contaminants
AU2019250882A1 (en) * 2018-04-12 2020-11-05 Amgen Inc. Methods for making stable protein compositions
CN114315990B (zh) * 2022-03-10 2022-05-27 北京康乐卫士生物技术股份有限公司 新型冠状病毒特异性单克隆抗体的制备及其应用
CN115074335B (zh) * 2022-06-20 2024-01-26 山东泰邦生物制品有限公司 一种磷酸三丁酯/聚山梨酯80病毒灭活试剂的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749783A (en) 1986-07-11 1988-06-07 Miles Laboratories, Inc. Viral inactivation and purification of active proteins
US5728821A (en) * 1994-08-04 1998-03-17 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
WO1998009660A1 (en) * 1996-09-06 1998-03-12 Epic Therapeutics, Inc. Viral inactivation of biological fluids with biomolecule activity retention
IL136552A (en) * 2000-06-05 2005-05-17 Omrix Biopharmaceuticals Ltd Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration
US7501494B2 (en) * 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
AU2005229674B2 (en) * 2004-11-18 2010-11-04 Kedrion Melville Inc. Low concentration solvent/detergent process of immuneglobulin with pre-treatment
CN100457896C (zh) * 2005-10-26 2009-02-04 李法卿 灭活生物制品中病毒和去除细菌内毒素的方法
WO2010048192A2 (en) * 2008-10-20 2010-04-29 Abbott Laboratories Viral inactivation during purification of antibodies
CN102985536B (zh) * 2010-04-14 2017-12-05 Emd密理博公司 生产高效价、高纯度的病毒母液的方法及使用其的方法
SG191184A1 (en) * 2010-12-15 2013-07-31 Baxter Int Viral inactivation using improved solvent-detergent method
CA2812739A1 (en) 2011-03-25 2012-10-04 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
KR102433719B1 (ko) * 2013-10-04 2022-08-17 엔진아이씨 몰레큘러 딜리버리 피티와이 리미티드 약물 로딩된, 이중특이성 리간드-표적화된 미니세포 및 인터페론 감마에 의한 복합 종양 치료
CN105722523B (zh) * 2013-11-15 2022-06-14 豪夫迈·罗氏有限公司 使用环保洗涤剂的病毒灭活方法
FR3025515B1 (fr) * 2014-09-05 2016-09-09 Lab Francais Du Fractionnement Procede de purification d'un anticorps monoclonal
CN104367591B (zh) * 2014-10-17 2018-02-23 同路生物制药有限公司 一种对血液制品的原料血浆进行病毒灭活处理的方法
CN106749660B (zh) * 2016-12-27 2020-02-14 嘉和生物药业有限公司 单克隆抗体下游纯化过程中有效去除宿主蛋白的方法
EP3446710A1 (en) 2017-08-25 2019-02-27 Glenmark Pharmaceuticals S.A. Methods of inactivating viral contaminants

Also Published As

Publication number Publication date
AU2018320524A1 (en) 2020-02-27
JP2024001035A (ja) 2024-01-09
AU2018320524B2 (en) 2021-08-26
US20190292221A1 (en) 2019-09-26
JP2021506226A (ja) 2021-02-22
WO2019038742A1 (en) 2019-02-28
CA3073309A1 (en) 2019-02-28
AU2021209148A1 (en) 2021-08-19
NZ761396A (en) 2024-05-31
KR20200045485A (ko) 2020-05-04
EP3672637A1 (en) 2020-07-01
US20200369747A1 (en) 2020-11-26
US20210324000A1 (en) 2021-10-21
EP3446710A1 (en) 2019-02-27
IL272779A (en) 2020-04-30
US20240002434A1 (en) 2024-01-04
US11884700B2 (en) 2024-01-30
BR112020003560A2 (pt) 2020-10-27
CN115716871A (zh) 2023-02-28
CN111050799A (zh) 2020-04-21
MX2020001920A (es) 2020-09-25

Similar Documents

Publication Publication Date Title
EA202090243A1 (ru) Способы инактивации вирусных загрязнений
CR20180518A (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
EA201890302A1 (ru) Химерные рецепторы антигенов на основе однодоменных антител и способы их применения
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
EA201992038A1 (ru) Анти-псф-тау-антитела и способы их применения
EA201890655A1 (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
EA201992206A1 (ru) Моноклональное антитело к pd-l1
EA201692157A1 (ru) Синтез двухцепочечных нуклеиновых кислот
CO2020000090A2 (es) Cromatografia
EA202091259A1 (ru) Способ получения опикапона и его интермедиатов
EA202092088A1 (ru) Антитела анти-phf-тау и их применение
EA202192923A1 (ru) Антитела и способы лечения инфекции, вызываемой вирусом гриппа а
PL439807A1 (pl) Sposoby oczyszczania przeciwciał i ich kompozycje
EA201990998A1 (ru) Фармацевтические составы и способы их получения
EA202090933A1 (ru) Способ получения гербицидных соединений пиридазинона
EA201890177A1 (ru) Мультиспецифические связывающие белки
EA201990270A1 (ru) Смеси, содержащие defi и тауратамиды, и способы их получения
MD3365367T2 (ro) Anticorpi monoclonali împotriva ploşniţelor de pat și procedee de obţinere și utilizare a acestora
PL439808A1 (pl) Sposoby i kompozycje hodowli komórkowych do produkcji przeciwciał
EA202192840A1 (ru) Способ получения соединений карбамоилоксиметилтриазолциклогексиловой кислоты
EA202192893A1 (ru) Среда для культивирования эукариотических клеток
EA202190330A1 (ru) Способ получения полиморфной формы робенакоксиба
EA202191338A1 (ru) Улучшенный способ производства т-клеток
SG11201810779PA (en) Method for screening antibody using patient-derived tumor spheroids
EA202191173A1 (ru) Моноклональное антитело, которое специфически связывается с cd20